License and Collaboration Agreements (Tables)

6 Months Ended

Jun. 30, 2018

Organization Consolidation And Presentation Of Financial Statements [Abstract]

License, Collaboration and Other Revenue

In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):

		Three months ended June 30,				Six months ended June 30,
Partner	Drug or Drug Candidate	2018		2017		2018		2017
Bristol-Myers Squibb	NKTR-214	$	1,059,768	$	—	$	1,059,768	$	—
Baxalta Incorporated/Shire	ADYNOVATE®		18		45		10,028		45
Eli Lilly and Company	NKTR-358		3,052		—		5,406		—
Amgen, Inc.	Neulasta®		1,250		1,250		2,500		2,500
AstraZeneca AB	MOVANTIK® and MOVANTIK® fixed-dose combination program		—		1,600		—		4,600
Other			158		1,929		271		3,771
License, collaboration and other revenue		$	1,064,246	$	4,824	$	1,077,973	$	10,916

Changes in Deferred Revenue Balance from Collaboration Agreements

The following table presents the changes in our deferred revenue balance from our collaboration agreements during the six months ended June 30, 2018 (in thousands):

	Six months ended June 30, 2018
Deferred revenue—December 31, 2017	$	37,970
Transition adjustment related to adoption of ASC 606		(1,953	)
Additions to deferred revenue		4,000
Recognition of previously unearned revenue		(8,249	)
Deferred revenue—June 30, 2018	$	31,768